Home › Bell Radar › APMD

APMDApnimed

US ExchangeHealth Care2026-07-31

Develops novel oral therapies targeting neuromuscular dysfunction in obstructive sleep apnea.

$16IPO price

$192MRaised

$25Day-1 close

78.44%Day-1 return

Develops novel oral therapies targeting neuromuscular dysfunction in obstructive sleep apnea.

Company description (source: StockAnalysis)

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

医疗健康生物医药临床制药

51CFO read: Requires CFO expertise in clinical-stage biopharma financial governance and FDA-path capital planning.

Management details per the SEC prospectus.

Company profile SEC prospectus

Does your company need this kind of CFO?

51CFO is an investment banking team focused on the US market: US IPOs, reverse mergers, shell deals, SPAC and De-SPAC, SEC filings and post-listing follow-ons, run by one team from structure to opening bell. Free 30-minute listing-route diagnosis, answered within 24 hours.

Talk to us